In the key Phase 3 ATTAIN-1 trial published in the New England Journal of Medicine in 2025, once-daily orforglipron 36 mg produced mean body weight reductions of 11.2% at 72 weeks in adults with obesity, with nearly 55% of participants achieving at least 10% weight loss and 36% achieving 15% or more
Side effects: Similarities and potential differences Weight loss patches currently available are not GLP-1 mimetics, and may not have the same side effects as GLP-1 drugs, like Wegovy, Ozempic, Mounjaro, or Zepbound
Dose Day context Dose Day is MeAgain's shot or pill routine checklist for the day you take your GLP-1
But I favored the Glow Serum and would definitely recommend it
When you provide proper support and remove obstacles, your natural detox and repair systems function remarkably well
Steroids should be avoided as they increase the amount of protein turnover and hence increase the nitrogen load, 43 strong recommendation, low quality evidence (1C)